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ABSTRACT 
The purpose of this study was to prepare solid dispersions (SD) of Glibenclamide (GLB) and evaluate them for in-vitro drug release 
enhancement. Glibenclamide is a second generation sulfonylurea antidiabetic drug used to control blood glucose in type 2 diabetic patients, but 
poor-water solubility is responsible for its low oral bioavailability which has severely restricted it in the clinical application for diabetic control. 
Therefore, to increase the aqueous solubility and thereby,  in-vitro dissolution of glibenclamide, solid dispersions were prepared with 
poloxamer-188in the ratio of 1:1, 1:2; 1:4 & 1:6 by solvent evaporation method in ethanol after conducting preliminary screening for the 
selection of best carrier and ratio for the development of solid dispersion of glibenclamide . Among the prepared SD formulations, GLB-SD4 (1:6 
Drug: Carrier ratio) showed highest enhancement in solubility and in-vitro dissolution rate in phosphate buffer (pH 6.8). In-vitro drug release 
profiles revealed that the drug release (%) of glibenclamide from GLB-SD4 was achieved 6-fold higher than pure drug after 180 mins. It is worth 
noting that GLB-SD4 provided the highest solubility and in-vitro dissolution rate compared to rest of the SD formulations, pure glibenclamide, 
market formulation and physical mixtures of glibenclamide in the same medium (Phosphate Buffer pH 6.8) as per the following manner: GLB-SD4 
> GLB-PM4 > GLB-MF>Pure GLB. This may be due to more reduction in particle size at molecular level, enhanced wetting properties and better 
solubilization of P-188 and use of ethanol. The hydrogen bonding interactions between the drug and carrier in the final solid dispersion 
formulation (GLB-SD4) was detected by Fourier Transform Infrared (FTIR) spectroscopy. These results demonstrated that the carrier (P-188) 
proved effective in improving the solubility of a poorly soluble glibenclamide, thereby endorsing the application of solid dispersion technology 
for the enhancement of solubility and thereby, in-vitro dissolution rate of glibenclamide. 
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1. INTRODUCTION 
Glibenclamide, also known as glyburide belongs to the 
second generation of oral anti-diabetic class of 
sulphonylurea. The chemical name of glibenclamide is 5-
Chloro-N-(2-{4-[(cyclohexylcarbamoyl) sulfamoyl] phenyl} 
ethyl)-2-methoxybenzamide and chemical formula is 
C23H28ClN3O5S (Figure 1). 
 
Figure 1 Chemical Structure of Glibenclamide 
 
The aqueous solubility of glibenclamide is 0.0025 mg/ml. 1 
There are two types of diabetes mellitus i.e. type 1 diabetes 
mellitus (T1DM) and type 2 diabetes mellitus (T2DM). T1DM 
is known as insulin-dependent diabetes mellitus, in which 
there is usually the autoimmune destruction of β-cells of 
pancreatic islets due to which the production of insulin is 
impaired. T2DM is known as non-insulin dependent diabetes 
mellitus in which there is either resistance to insulin and/or 
abnormal insulin secretion from β-cells of pancreatic islets. 2-
4 Glibenclamide is most frequently used as a drug of choice 
for the treatment of T2DM. Glibenclamide works by 
inhibiting the sulphonylurea receptor in β-cells of the 
pancreatic islets that ultimately leads to the opening of 
voltage-dependent calcium channel. This results in the 
increased concentration of intracellular calcium in β-cells 
that subsequently leads to the stimulation of insulin release. 
5 
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The present study was aimed to develop a formulation, 
which efficiently enhanced the aqueous solubility and in-
vitro dissolution rate of glibenclamide. The various 
approaches investigated till date includes particle size 
reduction, complexation and solid dispersion. 6 Among all 
these, solid dispersion is one of the most applicable 
formulation strategies extensively studied to improve the 
aqueous solubility and thereby, enhancement of in-vitro 
dissolution rate. 7 The methods of preparation include 
melting, solvent evaporation, etc. Poloxamer-188 had been 
previously shown to enhance drug solubilization in 
phosphate buffer. 8 The solid dispersion could improve 
solubility and in-vitro dissolution rate of a poorly water-
soluble drug by dispersing it at the molecular level in a 
biologically inert solid carrier. 
2. MATERIALS & METHODS 
Materials 
Glibenclamide was obtained from Lark Laboratories, Delhi 
and the purity was >99%.    Poloxamer-188 was obtained 
from cadila healthcare, Ahmedabad. Glibenclamide Tablets 
(Daonil, 10mg) were purchased from Sanofi Ltd. Ethanol was 
purchased from the supplier. All the other reagents and 
chemicals were of analytical grade. 
Methods 
2.1 Preliminary Screening of Carriers 9 
Various hydrophilic carriers (PEG-4000, PEG-6000, and 
Poloxamer-188) in different drug:polymer ratios (1:1, 1:2, 
1:4, 1:6) were analysed for their solubility enhancing 
potential of glibenclamide in phosphate buffer (pH 6.8). The 
excess amount of pure drug (10 mg) was taken in separate 
25 ml conical flasks and 15 ml of buffer was added to each 
flask. Then, the carriers were added as per the plan 
discussed in the Table 1. Both, weight of drug and volume of 
buffer were kept constant in each flask. The conical flasks 
were put in an orbital shaker (Remi orbital shaking 
incubator RIS-224BL) for 48 hours at 100 rpm at 37±0.5   C. 
Then, the solutions were kept for equilibration for 6 hours 
and then filtered through 0.45 µm filter. Each filtrate was 
suitably diluted with buffer and the amount of drug 
dissolved in buffer was estimated by UV Spectrophotometric 
(Labomed UVD 2950) method at λmax 300 nm. 
2.2 Preparation of solid dispersions (SDs) 10 
The solid dispersions of glibenclamide with poloxamer-188 
were prepared by a conventional solvent evaporation 
method. The weight ratios (1:1, 1:2, 1:4, 1:6) of drug to 
carrier were taken in different beakers containing ethanol. 
The beakers were placed in a water bath held at 40   C, till the 
solvent got evaporated completely from the solution in each 
beaker. Then the preparations were cooled immediately and 
kept overnight for solidification at room temperature. The 
solidified mass was pulverized by a pestle and the powder 
was passed through a 250 µm sieve to get uniformly sized 
particles and then the collected mass was stored in separate 
glass vials with tight lid and put in a dessicator till further 
analysis. 
2.3 Percent Practical yield (%PY) 11, 12 
Solid dispersions were collected and weighed to determine 
percent practical yield from the following equation. (Table 2 
& Figure 2) 
    
                                     
                                        
      
 
2.4 Percent Drug Content (%DC) 11, 13 
Solid dispersions equivalent to 10 mg of glibenclamide were 
weighed accurately and dissolved in 10 ml of methanol. The 
solution was filtered, diluted suitably and drug content was 
analyzed at 275 nm by UV spectrophotometrically. The drug 
content (%) was calculated using the following equation: 
(Table 3& Figure 3) 
    
                                       
                                          
      
2.5 Preparation of physical mixtures (PMs) 14 
Physical mixtures were prepared with glibenclamide and 
poloxamer-188 at the same weight ratios as discussed in the 
preparation of solid dispersions. In this, each component 
(drug and carrier) were accurately weighed out and simply 
triturated in the mortar with pestle for 15 minutes. The 
powder was passed through 250 µm sieve and the mass 
collected was stored in glass vial with tight lid and kept in a 
dessicator till further analysis. 
2.6 Saturation Solubility Studies 14, 15 
Saturation solubility studies of solid dispersions and physical 
mixture were conducted according to the method reported 
by Hecq et al. The solid dispersion and physical mixture 
formulations containing equivalent amount of drug (10 mg) 
were placed in a 25 ml conical flask with glass stopper 
containing 15 ml of buffer. The samples were placed in 
orbital shaker, agitated for 48 hours at 37±0.5 C until 
equilibrium was achieved and the aliquots were filtered 
through 0.45 µm filter. The filtered samples were suitably 
diluted with buffer and amount of glibenclamide estimated 
by UV-Spectrophotometrically at λmax 300 nm. (Table 4 & 
Figure 4) 
2.7 Fourier Transform Infra-Red Spectroscopy (FTIR) 16, 
17 
FTIR Spectroscopic analysis was carried using FTIR 
(NicoletTM iS5    T module  Thermo  isher Scienti ic  US ) 
by the potassium bromide pressed pellet techni ue. The 
samples  pure glibenclamide  poloxamer-    and solid 
dispersion  ere dried at 35  C for half an hour to ensure 
complete removal of moisture. The sample was scanned in 
4000–400 cm-1 region with the resolution of 4 cm-1 (Figure 
5.a, b, c) 
2.8 In vitro dissolution rate 18, 19, 20 
The in-vitro dissolution study was carried in USP Type II 
dissolution rate test apparatus (Bells India) using the paddle 
method. The release of glibenclamide was estimated by 
putting 10 mg pure glibenclamide and 10 mg equivalent of 
glibenclamide of solid dispersions, physical mixtures and 
market formulation (Daonil, 10mg). The in-vitro dissolution 
conditions maintained during the evaluation were, stirring 
rate of 100 rpm, temperature of  37±0.5   C, 900 mL of 
phosphate buffer (pH 6.8) as dissolution medium and 5 ml of 
the dissolution samples were withdrawn from the 
dissolution vessel  at predetermined time intervals at  15, 30, 
60, 90, 120,  and 180 minutes and simultaneously 
replenished with the addition of an equal volume of fresh 
dissolution medium maintained at the same temperature to 
keep the volume of dissolution medium constant and to 
maintain the sink conditions.  The withdrawn samples were 
immediately filtered through 0.45 µm filter and the filtrate 
was suitably diluted and amount of glibenclamide was 
estimated UV Spectrophotometrically at 300 nm at each time 
interval. (Table 5, 6 & Figure 6, 7) 
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3. RESULTS & DISCUSSION 
3.1Preliminary Screening of Carriers 
The preliminary screening of carriers was carried out as per 
the method discussed in section 2.1. It was observed that out 
of the three carriers, poloxamer-188 potentially enhanced 
the solubility more than PEG-4000 & PEG-6000 in the same 
medium and it was also found that the solubility of 
glibenclamide increased with increasing amount of the 
carrier and within the poloxamer-188 ratios, 1:6 recorded 
highest solubility of glibenclamide. So, on the basis of this 
screening, the poloxamer-188 was selected for further 
experimentation.
 
Table1 Preliminary Screening of Carriers 
Drug Polymer D:P 
Ratio  
Drug 
(mg) 
Carrier 
(mg) 
Solvent Solvent  
(ml) 
Solubility (mg/ml) 
(±SD) n=3 
GLB Pure 0.0025±0.0008 
GLB 
PEG-4000 
1:1 
10 
10 
Phosphate Buffer 
pH 6.8 
15 
0.042 ± 0.004 
1:2 20 0.057±0.001 
1:4 40 0.066±0.006 
1:6 60 0.071±0.003 
PEG-6000 
1:1 
10 
10 
 Phosphate Buffer 
pH 6.8 
15 
0.044±0.006 
1:2 20 0.061±0.002 
1:4 40 0.077±0.004 
1:6 60 0.089±0.002 
P-188 1:1 
10 
10 
Phosphate Buffer 
pH 6.8 
15 
0.122±0.005 
1:2 20 0.213±0.007 
1:4 40 0.248±0.005 
1:6 60 0.488±0.006 
 
3.2 Percent Practical yield 
The practical yield of solid dispersions was found to be between 91.66 % to 92.84 %. This reveals the efficiency of the method of 
preparation. 
Table 2: Percent Practical Yield of SDs of GLB (±SD); n=3 
Formulation Code Drug Carrier Drug-Carrier Ratio Drug Content (%) 
GLB-SD1 
GLB P-188 
1:1 92.66±0.04 
GLB-SD2 1:2 92.64±0.02 
GLB-SD3 1:4 92.67±0.06 
GLB-SD4 1:6 92.66±0.05 
 
 
Figure 2 Percent Practical Yield of SDs of GLB 
3.3 Percent Drug Content 
The drug content of solid dispersions was found to be between 99.76% to 99.78%. 
Table 3Percent Drug Content of SDs of GLB (±SD); n=3  
Formulation Code Drug Carrier Drug-Carrier Ratio Drug Content (%) 
GLB-SD1 
GLB P-188 
1:1 99.76±0.002 
GLB-SD2 1:2 99.76±0.003 
GLB-SD3 1:4 99.78±0.003 
GLB-SD4 1:6 99.76±0.001 
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Figure 3 Percent Drug Content of SDs of GLB 
3.4 Saturation Solubility Studies 
Table 4 Saturation Solubility Studies of SDS & PMs of GLB 
Formulation Code Drug Carrier D:C Ratio Solubility (mg/ml) 
(±SD); n=3 
GLB Pure  0.0025±0.02 
GLB-SD1 
GLB P-188 
1:1 0.255±0.01 
GLB-SD2 1:2 0.345±0.05 
GLB-SD3 1:4 0.531±0.03 
GLB-SD4 1:6 0.643±0.02 
GLB-PM1 1:1 0.052±0.05 
GLB-PM2 1:2 0.083±0.03 
GLB-PM3 1:4 0.132±0.02 
GLB-PM4 1:6 0.199±0.01 
 
 
Figure 4: Saturation Solubility Studies of SDs and PMs of GLB 
3.5 Fourier Transform Infra-Red Spectroscopy (FTIR) 
 
Figure 5.a FTIR of GLB Pure 
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Figure 5.b FTIR of P-188 
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Figure 5.c FTIR of GLB-SD4 
 
3.6 In-vitro dissolution studies 
The solid dispersion formulation (GLB-SD4) having 1: 6 
glibenclamide and poloxamer-188 ratio showed highest in 
vitro dissolution in the phosphate buffer than the rest of the 
solid dispersion formulations. The enhancement was 
approximately recorded as 6 fold higher than the pure 
glibenclamide in the same buffer conducted under same 
conditions as in dissolution of GLB-SD4. It was also, observed 
that the GLB-SD4 showed higher in-vitro dissolution than the 
physical mixtures prepared and market formulation. 
   
Table 5 in-vitro drug release of pure drug, SDs and MF of GLB in PB (pH 6.8) (± SD); n = 3 
Time (mins) Drug Released (%) 
 GLB-Pure GLB-SD1 GLB-SD2 GLB-SD3 GLB-SD4 GLB-MF 
15 01.58 09.07 18.77 29.44 36.67 06.96 
30 03.87 19.67 27.78 37.33 43.49 15.89 
60 06.45 28.88 36.68 41.99 53.65 21.67 
90 09.76 39.65 43.79 51.01 64.88 28.54 
120 11.57 45.89 54.77 64.67 77.17 37.78 
180 15.66 51.76 64.89 72.76 90.12 41.97 
 
 
Figure 6 in-vitro release of Pure drug, SDs and MF of GLB in PB (pH 6.8) (± SD); n = 3  
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Table 6 in-vitro drug release of pure drug and PMs of GLB in 
PB (pH 6.8) (± SD); n = 3 
Time 
(mins) 
Drug Released (%) 
 GLB-
Pure 
GLB- 
PM1 
GLB-
PM2 
GLB-
PM3 
GLB-
PM4 
15 01.58 04.12 06.11 08.98 07.34 
30 03.87 08.11 10.71 13.12 15.45 
60 06.45 12.87 14.99 17.89 22.78 
90 09.76 15.34 18.11 22.78 30.87 
120 11.57 17.99 22.89 28.76 36.67 
180 15.66 22.34 27.67 33.45 43.87 
 
 
Figure 7 in-vitro release of Pure drug, SDs and MFT of GLB in 
PB (pH 6.8) (± SD); n = 3 
4 CONCLUSIONS 
SDs of glibenclamide in poloxamer-188 were successfully 
prepared by the solvent evaporation method with excellent 
yield and the drug: polymer ratio significantly influenced 
GLB dissolution rate, as higher amounts of hydrophilic 
carrier led to enhanced drug dissolution i.e., 1:6 GLB: P-188 
ratio showed highest dissolution than rest of the SDs of 
glibenclamide, pure glibenclamide, market formulation and 
physical mixtures in phosphate buffer pH 6.8. The FTIR 
characterization revealed that there is hydrogen bonding 
interactions between drug and carrier. Thus, the present 
study demonstrated that SDs of GLB in P-188 prepared by 
the solvent evaporation method showed to be an effective 
way to overcome problems related to the poor aqueous 
solubility of this drug, improving its dissolution and thereby 
serving as a good release system for use in pharmaceutical 
formulations. 
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